Indication
Post-polycythemia Vera Myelofibrosis
14 clinical trials
18 products
1 drug
Clinical trial
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF PatientsStatus: Active (not recruiting), Estimated PCD: 2023-08-23
Product
RuxolitinibProduct
PelabresibProduct
PlaceboClinical trial
A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)Status: Recruiting, Estimated PCD: 2024-05-24
Product
Best Available TherapyProduct
NS-018Clinical trial
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)Status: Terminated, Estimated PCD: 2019-10-17
Clinical trial
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Status: Completed, Estimated PCD: 2017-07-18
Product
MMBProduct
MomelotinibClinical trial
A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor TherapyStatus: Completed, Estimated PCD: 2021-12-03
Product
DanazolProduct
PU-H71Clinical trial
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic NeoplasmsStatus: Withdrawn, Estimated PCD: 2022-10-20
Product
LNK01002Product
JaktinibClinical trial
Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With RuxolitinibStatus: Completed, Estimated PCD: 2022-08-03
Clinical trial
Observational Study Protocol REALFed - Real World Evidence of Fedratinib Effectiveness in MyelofibrosisStatus: Recruiting, Estimated PCD: 2026-01-01
Product
FedratinibClinical trial
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical StudyStatus: Recruiting, Estimated PCD: 2034-12-04
Product
BomedemstatClinical trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersStatus: Recruiting, Estimated PCD: 2025-11-28
Product
INCB000928Drug
ruxolitinibClinical trial
Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)Status: Completed, Estimated PCD: 2022-05-16
Product
AVID200Clinical trial
Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With MyelofibrosisStatus: Recruiting, Estimated PCD: 2027-12-20
Clinical trial
Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) InhibitionStatus: Recruiting, Estimated PCD: 2029-08-22
Product
TalazoparibProduct
pacritinibClinical trial
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)Status: Not yet recruiting, Estimated PCD: 2029-05-01
Product
Tasquinimod